A detailed history of Prosight Management, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Prosight Management, LP holds 192,700 shares of CYTK stock, worth $9.68 Million. This represents 2.73% of its overall portfolio holdings.

Number of Shares
192,700
Previous 230,000 16.22%
Holding current value
$9.68 Million
Previous $12.5 Million 18.35%
% of portfolio
2.73%
Previous 3.89%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.22 - $60.16 $1.91 Million - $2.24 Million
-37,300 Reduced 16.22%
192,700 $10.2 Million
Q2 2024

Aug 14, 2024

SELL
$47.86 - $75.05 $717,900 - $1.13 Million
-15,000 Reduced 6.12%
230,000 $12.5 Million
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $15.6 Million - $26.5 Million
245,000 New
245,000 $17.2 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.73B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Prosight Management, LP Portfolio

Follow Prosight Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.